All Stories

  1. Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
  2. Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group
  3. Safety Profile Comparison of Androgen Receptor Pathway Inhibitors: A Pharmacovigilance Signal Detection Analysis Using Disproportionality Methods and Age-Stratified Comparison of 37,875 FAERS Reports
  4. Immunosuppressive Tumor Microenvironment Signatures Predict Early Progression in NSCLC Patients Receiving Immune Checkpoint Inhibitors: A Transcriptomic and Immune Deconvolution Analysis of GSE135222
  5. Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions
  6. Psoas muscle indices, visceral fat distribution, inflammatory markers and 90-day mortality in palliative medicine: retrospective cohort study
  7. Modified albumin-bilirubin grade predicts overall and progression-free survival in metastatic gastric cancer
  8. Immune Checkpoint Inhibitors and Bone Health: Mechanisms, Clinical Implications, and Emerging Perspectives on Bone Fragility
  9. Evaluation of Inflammatory Parameters and Ferritin as Prognostic Factors in Non-small Cell Lung Cancer Patients Receiving Nivolumab Immunotherapy
  10. THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA
  11. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
  12. LOCALIZE SCROTAL KAPOSI SARCOMA IN A HIV-NEGATIVE PATIENT
  13. Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?
  14. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
  15. Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy
  16. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
  17. BEFORE & AFTER: THE EVALUATION OF THE EFFECT OF THE COVID-19 PANDEMIC ON CANCER PATIENTS IN PALLIATIVE CARE CENTER
  18. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)
  19. The Utility of the Cachexia Index and the Modified Glasgow Score in Young Patients With Breast Cancer
  20. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
  21. Cancer Care After the Earthquake? What Is Left to Us?
  22. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma
  23. After an Earthquake: The Comparison of Psychological Status of Resident and Earthquake Survivor Cancer Patients
  24. Laboratory Parameters Predicting Brain Metastasis in Patients with Lung Cancer
  25. The efficacy of IMDC score in Malignant Melanoma
  26. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
  27. Kanser hastalarında aşılanma durumu ve aşılanmayı etkileyen faktörlerin değerlendirilmesi
  28. Three Perspectives: The Approach of Neoadjuvant Treatment of Rectum Cancer According to Medical Oncologists, Radiation Oncologists, and Surgeons
  29. A New Prognostic Index in Young Breast Cancer Patients
  30. Microsatellite instability (MSI) in endometrial cancer; frequency and prognostic significance
  31. The Effect of COVID-19 on Radiation Oncology Practice in Türkiye
  32. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
  33. The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients
  34. Prognostic Value of Systemic Immune Index in Patients with Metastatic Gastric Cancer
  35. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
  36. The effect of body composition on prognosis in critically ill COVID-19 patients
  37. Investigation of the Effect of Tumor Location in Patients with Stage III Colon Cancer Receiving Adjuvant Oxaliplatine-Based Adjuvant Chemotherapy
  38. The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer
  39. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
  40. Intravenous Chemotherapy Adherence of Cancer Patients in Time of Covid-19 Crisis
  41. The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study
  42. Adjuvant chemotherapy in gastric cancer
  43. The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients
  44. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
  45. The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment
  46. The Effect of the Prognostic Nutritional Index on Chemoradiotherapy Response in Lung Cancer
  47. P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
  48. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group
  49. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study
  50. Are preoperative serum CA15-3 levels different in breast cancer subgroups?
  51. Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer
  52. Is TTF-1 a prognostic marker in non-small cell lung adenokarsinoma?
  53. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes
  54. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study
  55. Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.
  56. Cetuximab Treatment for Head and Neck Skin Cancer in a Patient with Heart Transplantation
  57. The Relationship Between the Level of Parathormone and the Existence and the Degree of Coronary Atherosclerosis
  58. Oxaliplatin induced acute immune-mediated thrombocytopenia; a case report